Apr 21, 2026
Welcome back to What’s it Worth! For over 70 years, the treatment of schizophrenia has been synonymous with dopamine D2 receptor blockade—until now. Join your host, Dr. Diana Langworthy, and guest Dr. Alexandra Rola (Psychiatry Clinical Pharmacist and Assistant Professor at Binghamton University) as they dive into...
Apr 2, 2026
Welcome back to What’s it Worth! In this episode, your host Dr. Diana Langworthy is joined by Mia Lussier, PharmD, MS, Clinical Assistant Professor at Binghamton University and ambulatory care specialist, to dissect the results of the SURPASS-CVOT trial . As the first large-scale trial directly comparing a dual...
Mar 20, 2026
Welcome back to What’s it Worth! Join your hosts, Dr. Diana Langworthy and guest Dr. Rachel Khan (Associate Professor at VCU School of Pharmacy), as they navigate the murky waters of renal function assessment in anticoagulant users. This episode dissects a critical insight from the ORBIT-AF II registry: the...
Feb 11, 2026
In this brief 2026 season opener, host Diana Langworthy, PharmD, BCPS pauses to acknowledge the weight of the moment—particularly here in Minnesota—where uncertainty, fear, and harm are being felt in very real ways across communities.
This episode is not about policy analysis or debate. It’s a reflection on what...
Dec 19, 2025
Welcome back What's it Worth? listeners.
This episode steps away from traditional trial critique. It’s a year-end reflection on what it means to practice evidence-based healthcare at a moment when trust in science, institutions, and clinicians is eroding—and when evidence itself is increasingly being misused to...